<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01321957</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-0209</org_study_id>
    <nct_id>NCT01321957</nct_id>
  </id_info>
  <brief_title>Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer</brief_title>
  <acronym>CHARTA</acronym>
  <official_title>FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of Irinotecan in combination
      with FOLFOX+Bevacizumab versus FOLFOX+Bevacizumab alone in the first-line treatment of
      patients with metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5-Fluorouracil and oxaliplatin (FOLFOX-Regimen) in combination with bevacizumab is regarded
      as standard first-line treatment in metastatic colorectal cancer [Saltz et al., 2008].
      Current studies established the role of the FOLFOXIRI regimen [Souglakos et al., 2006,
      Falcone et al., 2007]. A further intensification of the therapy seems feasible yielding
      response rates up to 84% and a disease control rate up to 100% [Falcone, 2008, Santomaggio,
      2009, Masi, 2010]. This trial evaluates the activity of an intensified first-line therapy for
      metastatic colorectal cancer compared to standard treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival rate</measure>
    <time_frame>9 months after first study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumour response according to RECIST v 1.1</measure>
    <time_frame>until progression of disease for a maximum of two years after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary resection rate</measure>
    <time_frame>for a maximum of two years after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rate</measure>
    <time_frame>until progression of disease for a maximum of two years after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>until death for a maximum of two years after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>18 months after the date of last study drug administration</time_frame>
    <description>Toxicity of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Until end of treatment (maximum 2 years after first study drug administration)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX+Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX+Bevacizumab+Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, 5FU/LV, Bevacizumab</intervention_name>
    <description>bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)</description>
    <arm_group_label>FOLFOX+Bevacizumab</arm_group_label>
    <other_name>Bevacizumab</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>I-LV</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan</intervention_name>
    <description>bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)</description>
    <arm_group_label>FOLFOX+Bevacizumab+Irinotecan</arm_group_label>
    <other_name>Bevacizumab</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>I-LV</other_name>
    <other_name>5-FU</other_name>
    <other_name>Irinotecan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed diagnosis of stage IV (UICC) colorectal cancer
             (primary tumor may be present)

          2. Patients with at least one measurable lesion, with size &gt; 1 cm (RECIST v1.1)

          3. ECOG Performance status ≤ 2 (ECOG 2, only if tumor related)

          4. Patients, who are able to tolerate intensive first lien treatment as judged by the
             investigator

          5. Life expectancy &gt; 3 months

          6. Age ≥ 18 years

          7. Haematologic function: ANC ≥ 1.5 x 109/L, platelets ≥ 100 x109/L, hemoglobin

               -  9 g/dl or 5.59 mmol/l

          8. Patients not receiving therapeutic anticoagulation must have an INR &lt; 1.5 ULN and aPTT
             &lt; 1.5 ULN within 7 days prior to registration. The use of full dose anticoagulants is
             allowed as long as the INR or aPTT is within therapeutic limits (according to the
             medical standard in the institution) and the patient has been on a stable dose for
             anticoagulants for at least two weeks at the time of registration.

          9. Adequate liver function as measured by serum transaminases (AST &amp; ALT) ≤ 2.5 x ULN (in
             case of liver metastases &lt; 5 x ULN) and total bilirubin ≤ 1.5 x ULN

         10. Adequate renal function: Serum creatinine ≤ 1.5 x ULN

         11. Signed, written informed consent

        Exclusion Criteria:

          1. Patients with histologically confirmed diagnosis of stage IV (UICC) colorectal cancer
             (primary tumor may be present)

          2. Patients with at least one measurable lesion, with size &gt; 1 cm (RECIST v1.1)

          3. ECOG Performance status ≤ 2 (ECOG 2, only if tumor related)

          4. Patients, who are able to tolerate intensive first lien treatment as judged by the
             investigator

          5. Life expectancy &gt; 3 months

          6. Age ≥ 18 years

          7. Haematologic function: ANC ≥ 1.5 x 109/L, platelets ≥ 100 x109/L, hemoglobin

               -  9 g/dl or 5.59 mmol/l

          8. Patients not receiving therapeutic anticoagulation must have an INR &lt; 1.5 ULN and aPTT
             &lt; 1.5 ULN within 7 days prior to registration. The use of full dose anticoagulants is
             allowed as long as the INR or aPTT is within therapeutic limits (according to the
             medical standard in the institution) and the patient has been on a stable dose for
             anticoagulants for at least two weeks at the time of registration.

          9. Adequate liver function as measured by serum transaminases (AST &amp; ALT) ≤ 2.5 x ULN (in
             case of liver metastases &lt; 5 x ULN) and total bilirubin ≤ 1.5 x ULN

         10. Adequate renal function: Serum creatinine ≤ 1.5 x ULN

         11. Signed, written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Joachim Schmoll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Halle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Bottrop</name>
      <address>
        <city>Bottrop</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis</name>
      <address>
        <city>Bottrop</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dessau</name>
      <address>
        <city>Dessau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhhaus Dinslaken</name>
      <address>
        <city>Dinslaken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hämatologie-Onkologie</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozenrum Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologie Duisburg</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Georg Klinikum Eisenach gGmbH</name>
      <address>
        <city>Eisenach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Krankenhaus St. Johann Nepomuk</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>pioh Praxis</name>
      <address>
        <city>Frechen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Partnerschaft FÄ für Innere Medizin</name>
      <address>
        <city>Freiberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Osthessen GmbH</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Gummersbach GmbH</name>
      <address>
        <city>Gummersbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienkrankenhaus Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Überörtliche Gemeinschaftspraxis für Innere Medizin</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Region Hannover GmbH,</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Schröder</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Heidenheim</name>
      <address>
        <city>Heidenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP Hämatologie u. Internistische Onkologie</name>
      <address>
        <city>Hennigsdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis im Medicinum</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bernward Krankenhaus</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanaklinikum Hof GmbH</name>
      <address>
        <city>Hof</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für med. Dokumentation, Gutachtenerstellung, Gesundheitsförderung u. Qualitätssicherung GbR</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Cincentius-Kliniken gAG</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studiengesellschaft Kátay + Reiser GbR</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Innere Medizin und Gastroenterologie</name>
      <address>
        <city>Köthen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Innere Medizin</name>
      <address>
        <city>Laatzen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum - Lahr Ettenhaim</name>
      <address>
        <city>Lahr</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. med. Veling-Kaiser</name>
      <address>
        <city>Landshut</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum Mitte</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onco Studies Lörrach-OSL an der Schwerpunktpraxis Onkologie Dreiländereck</name>
      <address>
        <city>Lörrach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg gGmbH</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistisches Fachzentrum mit Dialyse, Onkologische Praxis am Klinikum</name>
      <address>
        <city>Memmingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Ebert-Krankenhaus Neumünster GmbH</name>
      <address>
        <city>Neumünster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PIUS-Hospital Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedResearch - Medizinisches Studien- u. Dokumentationszentrum Leipziger Land</name>
      <address>
        <city>Rötha</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Innere Medizin, Hämatololgie und Onkologie</name>
      <address>
        <city>Schkeuditz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leopoldina Krankenhaus der Stadt Schweinfurt GmbH</name>
      <address>
        <city>Schweinfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromäerinnen gGmbH</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisnetzwerk Hämaologie/Intern. Onkologie</name>
      <address>
        <city>Troisdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ammerland-Klinik GmbH</name>
      <address>
        <city>Westerstede</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft für Onkologie und Urologie Wilhelmshaven</name>
      <address>
        <city>Wilhelmshaven</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Mathias Schulze</name>
      <address>
        <city>Zittau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2011</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Hans-Joachim Schmoll, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

